Adintrevimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and other SARS-like CoVs, that can potentially be used for immunization against COVID-19. Upon administration, adintrevimab specifically targets and binds to a highly conserved epitope in the receptor-binding domain (RBD) of SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.

**Synonyms:** - ADG 20 - ADG-20 - ADG20 - ADINTREVIMAB